摘要:
The present invention relates to a proteinaceous construct comprising plasmatic or recombinant factor VIIa (F Vila) or biologically active derivatives thereof, which are bound to a carbohydrate moiety comprising 1-4 sialic acid units, wherein the in vivo half-life of the proteinaceous construct is substantially prolonged in the blood of a mammal, as compared to the in vivo half-life of a FVIIa molecule not bound to a carbohydrate moiety. The invention also provides a method for controlling bleeding in a mammal having a bleeding disorder due to functional defects or deficiencies of FVIIa, FVIII, or FIX. The invention also provides a method for controlling bleeding in a mammal during surgery or trauma.
摘要:
The present invention relates to a proteinaceous construct comprising plasmatic or recombinant factor VIIa (F VIIa) or biologically active derivatives thereof, which are bound to a carbohydrate moiety comprising 1-4 sialic acid units, wherein the in vivo half-life of the proteinaceous construct is substantially prolonged in the blood of a mammal, as compared to the in vivo half-life of a FVIIa molecule not bound to a carbohydrate moiety. The invention also provides a method for controlling bleeding in a mammal having a bleeding disorder due to functional defects or deficiencies of FVIIa, FVIII, or FIX. The invention also provides a method for controlling bleeding in a mammal during surgery or trauma.
摘要:
The present invention pertains to anti-MIF antibodies, in particular their use in combination with cancer therapeutics, i.e. chemotherapeutics, in the treatment of cancer.
摘要:
A peptide or peptide derivative comprising: (i) WDLYFEIVW (SEQ ID NO: 1); or (ii) a variant amino acid sequence comprising one, two, three or four L-amino acid substitutions in WDLYFEIVW (SEQ ID NO: 1); or (iii) the retro-inverso variant of the peptide or peptide derivative of either one of parts (i) and (ii), wherein said peptide or peptide derivative has procoagulant activity. A peptide or peptide derivative comprising: (i) an amino acid sequence comprising imfwydcye; or (ii) a variant amino acid sequence comprising one, two, three, four, five or six amino acid substitutions in imfwydcye, wherein said peptide or peptide derivative has procoagulant activity.
摘要翻译:一种肽或肽衍生物,其包含:(i)WDLYFEIVW(SEQ ID NO:1); 或(ii)在WDLYFEIVW(SEQ ID NO:1)中包含一个,两个,三个或四个L-氨基酸取代的变体氨基酸序列; 或(iii)部分(i)和(ii)中任一项的肽或肽衍生物的逆转型变体,其中所述肽或肽衍生物具有促凝活性。 一种肽或肽衍生物,其包含:(i)包含成纤维细胞的氨基酸序列; 或(ii)在成纤维细胞中包含一个,两个,三个,四个,五个或六个氨基酸取代的变体氨基酸序列,其中所述肽或肽衍生物具有促凝活性。